Convert Pharmaceuticals SA

Convert Pharmaceuticals SA is a biopharmaceutical company focused on developing innovative hypoxia-activated prodrugs aimed at effectively targeting and treating solid tumors, including pancreatic and ovarian cancers. Founded in 2017 in Liege, Belgium, Convert Pharmaceuticals SA specializes in hypoxia-activated prodrugs (HAPs) that become active specifically at tumor sites. The company has raised EUR 13. 6 mn in funding from investors including Droia Ventures and the Walloon Region of Belgium, with the latest funding round occurring in March 2018.

Convert Pharmaceuticals has engaged in one total deal to date. Convert Pharmaceuticals specializes in the development of hypoxia-activated prodrugs (HAPs), which are designed to remain inert until they reach the tumor site, where they are activated into potent anti-cancer agents. This innovative approach addresses tumor hypoxia—a condition prevalent in approximately 50% of solid tumors—thus targeting a significant challenge in oncology. The company's aim is to create targeted therapies for various cancer types, including pancreatic, ovarian, breast, prostate, and head and neck squamous cell carcinomas, by leveraging proprietary insights into tumor biology and specific biomarkers.

Convert Pharmaceuticals provides its therapies to healthcare providers, research institutions, and pharmaceutical partners across Europe, North America, and Asia. Convert Pharmaceuticals operates as a privately held company with revenue generated through strategic partnerships with healthcare providers and research institutions. These partnerships may lead to collaborative research agreements or clinical trial funding, generating revenue upon successful trials or licensing arrangements. The company's flagship products, particularly the hypoxia-activated prodrugs, are positioned for commercial use following regulatory approvals, with transactions likely structured through B2B arrangements with healthcare organizations purchasing these therapies directly for patient use or collaborating with pharmaceutical companies for co-development and distribution.

In 2022, the company's EBITDA amounted to EUR 6,235. 3. Convert Pharmaceuticals plans to use the EUR 13. 6 mn raised in March 2018 to fund the ongoing development of its hypoxia-activated prodrugs and to potentially expand into new markets.

The company is focused on launching upcoming products tailored to specific patient populations, which may include targeted therapies for additional cancer types. Plans for expansion include targeting markets in North America and Asia within the next few years, leveraging recent investments to enhance their product pipeline and facilitate entry into these regions.